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The contraction pattern of the heart relies on the activation and conduction of the electrical impulse. Per-
turbations of cardiac conduction have been associated with congenital and acquired arrhythmias as well as 
cardiac arrest. The pattern of conduction depends on the regulation of heterogeneous gene expression by key 
transcription factors and transcriptional enhancers. Here, we assessed the genome-wide occupation of conduc-
tion system–regulating transcription factors TBX3, NKX2-5, and GATA4 and of enhancer-associated coactiva-
tor p300 in the mouse heart, uncovering cardiac enhancers throughout the genome. Many of the enhancers 
colocalized with ion channel genes repressed by TBX3, including the clustered sodium channel genes Scn5a, 
essential for cardiac function, and Scn10a. We identified 2 enhancers in the Scn5a/Scn10a locus, which were 
regulated by TBX3 and its family member and activator, TBX5, and are functionally conserved in humans. We 
also provided evidence that a SNP in the SCN10A enhancer associated with alterations in cardiac conduction 
patterns in humans disrupts TBX3/TBX5 binding and reduces the cardiac activity of the enhancer in vivo. 
Thus, the identification of key regulatory elements for cardiac conduction helps to explain how genetic vari-
ants in noncoding regulatory DNA sequences influence the regulation of cardiac conduction and the predis-
position for cardiac arrhythmias.
Introduction
Abnormal heart rhythms are common and cause significant 
morbidity and mortality. Arrhythmias may present around birth 
as part of a congenital heart defect, the most common etiology 
of birth abnormalities. However, the majority of arrhythmias 
develop with increasing age or as a comorbidity. These include 
sinus node dysfunction, atrioventricular (AV) block, and atrial 
fibrillation, the most common arrhythmia encountered in clini-
cal practice causing significant morbidity and mortality (1). 
Sudden cardiac death from ventricular fibrillation, occurring 
mostly in the setting of coronary heart disease, is a leading cause 
of death (2). Although molecular, genetic, and physiological 
mechanisms have been described, most of the underlying causes 
are insufficiently understood (3).
Rhythmic and synchronized contraction of the atria and ven-
tricles of the heart crucially relies on the proper generation and 
conduction of the cardiac electrical impulse. This process necessi-
tates localized cardiomyocyte specialization in the different heart 
components (atria, AV node, ventricular conduction system, etc.) 
and demands that the cells possess specific electrophysiological 
characteristics. These intrinsic heterogeneities are rooted, at least 
in part, in the regional, compartment-specific differences in ion 
channel and gap junction gene expression, the defining factors of 
electrophysiology that derive action potential shape and intercel-
lular propagation of the impulse (4–8).
The development and function of the heart components is 
driven by a set of interacting DNA binding transcription factors 
and chromatin remodeling proteins that form evolutionarily con-
served regulatory networks (9–11). These transcription factors 
interact with specific noncoding regulatory DNA sequences (i.e., 
enhancers) of many genes to activate or repress their activity. It 
is becoming increasingly clear that these same transcription fac-
tors play essential roles in regulating regionalized expression of 
ion channel and gap junction genes, affecting cardiac electrophysi-
ology. Hallmark examples include transcription factors essential 
for heart development (e.g., NKX2-5 and TBX5), which activate 
gap junction subunit–encoding genes (e.g., CX40, encoded by 
Gja5) and ion channel genes and which, when mutated, can bring 
about electrical abnormalities such as AV conduction block and 
atrial fibrillation in humans (12–17). TBX2 and TBX3 are spe-
cifically expressed in — and critical for the development of — the 
sinus node, AV canal (AVC), and derived AV node and AV bundle 
(18–21). These factors may compete with TBX5 for the same DNA 
binding sites, but repress expression of gap junction proteins 
(e.g., CX40 and CX43) and ion channels (e.g., the sodium channel 
Scn5a) in pacemaker tissues of the sinus node and AVC (18, 22). 
The interplay between transcription factors expressed in broader 
patterns (i.e., TBX5 is expressed in atria and entire conduction 
system) and factors that display restricted patterns (i.e., TBX3 is 
expressed in sinus node and AV conduction system) provide essen-
tial contributions to the electrical pattern of the heart (refs. 11, 
16, 18, 23–28, and Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI62613DS1).
A series of genome-wide association studies (GWAS) (29–33) 
revealed that common variants in the population link genomic 
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regions that modulate cardiac impulse conduction and repolariza-
tion, disturbances that increase the risk of arrhythmia. Interesting-
ly, these variants were linked to essential cardiac transcription fac-
tors (e.g., NKX2-5, TBX5, and TBX3) and ion channels (e.g., SCN5A 
and SCN10A). Several of the variants were identified in noncoding 
sequences nearby these genes, which indicates that they represent 
potential enhancers controlling the localized and tissue-specific 
expression of these genes. These observations indicated that 
variants in regulatory elements of ion channel genes modulate 
development and homeostasis of the localized electrophysiologi-
cal properties of the heart. However, the difficulties involved in 
the identification of functional enhancers in vivo has meant that 
insight into this process is lacking.
Here we investigated the transcriptional network by assessing 
the genome-wide DNA interaction of the key cardiac transcription 
factors TBX3/TBX5, NKX2-5, and GATA4 and of the ubiquitously 
expressed enhancer-associated factor p300 (34–37) in the mouse 
heart in vivo, and identified many candidate cardiac enhancers. 
We further analyzed how known human genetic variants in these 
cardiac enhancers may affect transcription factor binding, and 
thus their activity. For the first time to our knowledge, we provide 
functional explanations for the effects of variants in noncoding 
DNA on cardiac conduction and arrhythmias.
Results
ChIP-seq analysis in adult mouse hearts and de novo definition of consensus 
transcription factor binding sites. The genome-wide occupancy profile 
of TBX3 in the heart was assessed using ChIP–massive parallel 
sequencing (ChIP-seq) analysis (38). Tbx3 is only expressed in the 
conduction system of the heart, a very small fraction of the total 
adult heart that is too small for ChIP-seq analysis (22). Therefore, 
Tbx3 expression was induced in all myocardial cells using mice 
with a Cre-inducible Tbx3 expression cassette (CT3) (18) and a 
cardiomyocyte-specific tamoxifen-inducible Cre expression cas-
Figure 1
In vitro validation of ChIP-seq datasets. (A) Overlap of all ChIP-seq binding regions with genes in refGene plus their promoters, defined here as 
the 1-kb upstream region of those genes. Values are percentage of all peaks. See Methods for a detailed description of peak definition. (B) Results 
obtained from the MEME motif discovery analysis. Binding motifs were in good agreement with those recently published for the HL-1 based 
ChIP-seq (35) and JASPAR motifs. (C) Number of overlapping binding regions between heart-derived ChIP-seq datasets. (D) ChIP-qPCR assay 
validating ChIP-seq peaks. Regions were randomly chosen from the group of ChIP-seq peaks that showed overlap between ChIP sequencing 
datasets for TBX3, GATA4 and NKX2-5. Shown is enrichment relative to Hprt for NKX2-5, GATA4, and TBX5 in WT adult mouse hearts and for 
TBX3 in TBX3-induced adult hearts. Ratios below represent the proportion of peaks that showed relative enrichment of more than 10. (E) Of the 
regions tested with ChIP-qPCR, 11 were tested for their response to NKX2-5, GATA4, and TBX5 or TBX3 in Cos7 cells. All enhancers responded 
to stimulation with GATA4 and NKX2-5. *P < 0.05.
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sette (Myh6-mER-Cre-mER) (39). At 1 day after the last treatment 
with tamoxifen, animals appeared healthy, but showed strong 
downregulation of known TBX3 targets, including Gja1 (encod-
ing CX43) and Gja5 (encoding CX40) (40). We reasoned that 
ectopically expressed TBX3 in the working myocardium would 
reveal binding sites normally occupied by TBX3 in the conduction 
system myocardium. However, TBX3 and TBX5 (members of the 
TBX2 subfamily expressed in adult heart) recognize highly similar 
binding sites, which indicates that this approach may also reveal 
TBX5 binding sites. Unfortunately, whereas ChIP of TBX5 was 
successful, we repeatedly failed to sequence enriched fragments 
because of technical problems during sequence library construc-
tion. Therefore, we performed ChIP–quantitative PCR (qPCR) and 
established that endogenous TBX5 in the adult heart interacted 
with the sites occupied by ectopically expressed TBX3 (see below). 
We also established the occupancy of endogenous NKX2-5 and 
GATA4, 2 cardiac transcription factors that cooperate with T-box 
factors (41). It has previously been shown that occupancy by the 
enhancer-associated protein p300 can predict the location of heart 
enhancers (34). To address this, we determined the occupancy pro-
file of p300 (Supplemental Figure 2). In all cases we used ChIP-
grade antibodies against the native factors.
We first evaluated the quality of our ChIP-seq experiments by 
determining the overlap in peaks between the TBX3 and control 
ChIP-seq datasets. These datasets possessed a total of 25,446 and 
1,089 peaks, respectively, with an overlap of 131. The overlapping 
peaks were subtracted from the main TBX3 dataset as likely false 
positive peaks. Next, we determined the number of peaks for both 
the NKX2-5 and the GATA4 ChIP-seq datasets (Figure 
1A), similarly removing peaks that overlapped with the 
control dataset. The resulting datasets were used to ana-
lyze the distribution of factor binding regions across 
the genome. For this analysis, a promoter region of 1 kb 
upstream of all genes was used to define the number of 
peaks associated with a promoter. The distribution of the 
remaining peaks was then assessed in terms of intragen-
ic or intergenic. This analysis revealed that the majority 
of peaks in all 3 datasets were positioned within a gene 
sequence (exons and introns), with a significant enrich-
ment of peaks associated with a promoter region (P < 
0.001). Our p300 data in general were in good agreement 
with the published data (34–36).
To investigate whether the ChIP peaks directly corre-
late to DNA binding elements for TBX3/TBX5, NKX2-
5, and GATA4, we performed de novo motif discovery 
using MEME (42). Using 600 random peaks of each 
transcription factor, our MEME analysis yielded motifs 
(Figure 1B) in good agreement with those derived from ChIP-seq 
data of biotinylated TBX5, NKX2-5, and GATA4 expressed in 
HL-1 cells (ref. 35 and Supplemental Figure 3). We found near-
perfect matches for the GATA4 motif in the JASPAR (43, 44) and 
TRANSFAC (45) databases. Interestingly, the NKX2-5 ChIP-seq 
motif showed a closer resemblance to the NKX3-2 consensus site 
found in the JASPAR database, compared with the NKX2-5 con-
sensus site. The ChIP-seq motif for TBX3/TBX5 resembled the 
motif for T in the JASPAR database and for TBX5 in the TRANS-
FAC database.
TBX3, TBX5, NKX2-5, and GATA4 are known to interact with 
each other in the regulation of transcription (46, 47). Recent ChIP-
seq analysis of biotinylated TBX5, NKX2-5, and GATA4 in HL-1 
cells indicated that overlapping peak regions often represent bona 
fide regulatory elements (35). Therefore, we assessed the intersec-
tions of our in vivo TBX3/TBX5, NKX2-5, and GATA4 datasets 
(Figure 1C) and found that the intragenic portion of the 185 
overlapping peak regions was significantly enriched for GO terms 
for heart and muscle system development (Supplemental Figure 
4A). Comparison of terms associated with the molecular function 
of the NKX2-5–GATA4 overlap and the TBX3–NKX2-5–GATA4 
intersect revealed that inclusion of TBX3 resulted mainly in an 
enrichment of terms associated with ion binding (Supplemental 
Table 4). Furthermore, we found an overlap of 63.2% of TBX3 
peak regions with the TBX5 dataset derived from HL-1 cells (35), 
demonstrating good correlation between the binding peak data of 
these closely related T-box proteins, despite the difference between 
the 2 experimental systems. Conversely, the TBX20 peak dataset 
(48) showed only a 17.8% overlap with our TBX3 dataset, consis-
tent with the observed difference in binding motif.
We selected 21 peak regions occupied by TBX3, NKX2-5, and 
GATA4 and validated binding in adult mouse hearts using ChIP-
qPCR (Figure 1D). A mean enrichment of 70- to 80-fold was 
observed for the transcription factors at these genomic locations. 
Furthermore, of 45 TBX3-occupied sites tested, 43 were occupied 
by endogenous TBX5. In addition, 22 of 25 tested genomic sites 
were also occupied by endogenous TBX3 in the developing heart 
(Supplemental Figure 5). These data support the notion that TBX3 
and TBX5 recognize the same sites in vivo and that ChIP of TBX3 
ectopically expressed in the adult heart occupies sites bound by 
endogenous TBX5. Using a luciferase reporter analysis, we next 
Table 1
Comparison of TBX3 peak–containing gene sets enriched or 
reduced in AVC with those induced or suppressed by TBX3
TBX3 peak TBX3-induced TBX3-suppressed Nonenriched 
associated   controls
Enriched AVC 118 (20.4) 73 (13.9) 36 (6.2 ± 0.9)
Reduced AVC 117 (20.2) 182 (34.7)A 50.3 (9.6 ± 1.0)
Values are expressed as number of genes (% of total genes). n = 6 non-
enriched controls. AP < 0.01 versus all other groups.
Table 2
GO term analysis associated with molecular function
Genes Count % P
Metal ion binding 67 26.9 1.00 × 10–3
Ion binding 68 27.3 1.10 × 10–3
Cation binding 67 26.9 1.30 × 10–3
Gated channel activity 11 4.4 2.50 × 10–3
Calmodulin binding 7 2.8 2.80 × 10–3
NAD(P)+-protein-arginine ADP-ribosyltransf. act. 3 1.2 3.00 × 10–3
Cation channel activity 10 4 3.50 × 10–3
Channel activity 12 4.8 5.40 × 10–3
Passive transmembrane transporter activity 12 4.8 5.40 × 10–3
Voltage-gated ion channel activity 8 3.2 6.60 × 10–3
Voltage-gated channel activity 8 3.2 6.60 × 10–3
Ion channel activity 11 4.4 1.10 × 10–2
GO term analysis was performed using DAVID. See Supplemental Tables 2–4 for 
additional GO analyses.
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tested 11 of these 21 regions for their response to TBX3, TBX5, 
NKX2-5, and GATA4 in transient transfection assays (Figure 1E). 
All fragments were stimulated to varying degrees by NKX2-5 and 
GATA4. The effect of addition of TBX3 or TBX5 was variable, prob-
ably reflecting the complexity of enhancer function. Taken togeth-
er, these results confirmed interaction of TBX3, TBX5, NKX2-5, 
and GATA4 with regions identified by ChIP-seq and that these 
regions acted as enhancers responding to the transcription factors.
Overlapping peak regions and gene expression arrays functionally clas-
sify TBX3 targets as conduction genes. TBX3 plays a critical role in the 
suppression of gene expression in the pacemaker and conduc-
tion system components (18, 22, 23). We hypothesized that genes 
expressed at lower levels in the AVC/AV node compared with the 
working myocardium are expected to be enriched in genes regulat-
ed directly by TBX3. We analyzed the overlap between the gene set 
containing TBX3 peaks and a set of genes differentially expressed 
between the AVC/AV node and working myocardium (Supplemen-
tal Table 1 and ref. 22). The set of genes reduced in the AVC dis-
played the greatest enrichment (Supplemental Figure 4B), which 
indicates that TBX3 is involved in the direct suppression of this 
subgroup of genes. Next, we correlated TBX3 binding and TBX3-
mediated gene regulation by combining the gene set containing 
TBX3 peaks with genes differentially expressed in heart tissue of 
the mice expressing tamoxifen-induced TBX3 and controls. The set 
of genes suppressed by TBX3 contained significantly more TBX3 
binding sites compared with the induced or control gene sets (Sup-
plemental Figure 4B). To further refine the identification of direct 
TBX3 gene targets, we compared sets of genes containing TBX3 
peaks and enriched or reduced in AVC with those induced or sup-
pressed by TBX3, leading to significant enrichment (Table 1). We 
hypothesize that the significantly enriched set of 182 genes (P < 
0.01 versus the other sets) occupied by TBX3, suppressed by ectopic 
TBX3 expression, and reduced in the TBX3-positive AVC/AV node 
would reveal targets directly suppressed by TBX3 in the AVC/AV 
node in vivo (Table 1 and Supplemental Figure 4B). Gene Ontol-
ogy (GO) term analysis using DAVID (49, 50) revealed that these 
genes were enriched for the terms ion transport, ion channels, and gap 
junctions (Table 2).
The enrichment of ion channel genes in the overlap analysis of 
TBX3 ChIP-seq peaks and AVC microarray data and the known 
role of TBX3 in conduction system and nodal development and 
homeostasis (18, 51–53) prompted us to analyze the response of 
10 of these ion channel genes to induced TBX3 expression in the 
myocardium. All genes analyzed, including Scn5a and Scn10a, were 
found to be significantly downregulated in the presence of TBX3 
in the working myocardium (Figure 2), while reference genes such 
as Gapdh, Hprt, Nkx2-5, and Gata4 were unaffected by the presence 
of TBX3 (Supplemental Figure 6).
Regulation of the Scn5a/Scn10a sodium channel gene locus by TBX3. 
SCN5A encodes Nav1.5, the main sodium channel responsible 
for rapid depolarization. Mutations in SCN5A underlie multiple 
inherited arrhythmia syndromes (26, 28). SCN10A (encoding 
Nav1.8) has only recently been implicated in cardiac conduction 
in a series of GWAS (30–33, 54). Several observations suggested 
that Scn5a and Scn10a are regulated in a coordinated fashion by 
TBX3 and TBX5. Scn5a and Scn10a were positioned adjacently 
in the genome, both contained sites occupied by TBX3/TBX5 
and other factors (Figure 3A), and both were readily downregu-
lated by TBX3. Both genes had similar relative spatial and tem-
poral expression profiles (for description of the Scn5a profile, 
see refs. 55, 56), although Scn5a expression was stronger than 
that of Scn10a, and its level increased in the ventricles toward 
the end of gestation (Supplemental Figure 7A). In situ hybrid-
ization showed that both genes had very similar expression pat-
terns: expressed in the atria; strongest in the mediastinal atrial 
walls (body of atria); and weaker in the auricles and in the tra-
becules and crest of the interventricular septum, the precursors 
of the ventricular conduction system components (Figure 3B). 
This pattern resembled that of TBX5, a transcriptional activator 
expressed in atria and conduction system. Moreover, expression 
was absent from the TBX3-positive sinus node and AVC/AV node 
(Figure 3C), consistent with the notion that TBX3 suppresses 
these genes in its own expression domain. The genes flanking 
these 2 sodium channels, Scn11a and Exog, showed no binding 
regions for TBX3 and were not significantly downregulated by 
TBX3 (Supplemental Figure 7B), which indicates that TBX3-
mediated regulation of this locus is likely to be confined to Scn5a 
and Scn10a. Taken together, these data indicate that Scn5a and 
Scn10a are coregulated, and that this process involves TBX3.
Identification of enhancers in the Scn5a/Scn10a locus. To gain 
insight into the mechanism of Scn5a/Scn10a regulation, we 
selected 9 fragments (F1–F9) in the Scn5a/Scn10a locus occu-
pied by TBX3 for functional analysis using luciferase reporter 
assays (Figure 4A). Of these regions, 4 (F1, F2, F4, and F9) also 
Figure 2
TBX3 is involved in the coordinated regulation of conduction genes. Quantitative RT-PCR analysis showed downregulation of 10 representa-
tive ion channel genes in atria of induced TBX3–expressing compared with control mice. These genes were significantly reduced in the AVC 
(P < 0.05) and contained ChIP-seq peaks for TBX3, GATA4, and NKX2-5. *P < 0.05.
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contained NKX2-5, GATA4, and p300 peaks (Figure 3A) and 
overlapped with the TBX5 datasets (35). F1 and F2, located in 
a noncoding part of Scn10a, were strongly activated by NKX2-5 
and GATA4. F9, located downstream of Scn5a, showed strong 
constitutive activity in H10 cells (Figure 4B). This effect was 
also observed for F4, located in a noncoding part of Scn5a that 
contains a region previously reported to affect Scn5a expres-
sion and thus modulate sodium channel function in vivo (57). 
Using an independent PCR-based assay, we confirmed the asso-
ciation of TBX3, TBX5, NKX2-5, and GATA4 with the mapped 
ChIP-seq positions to variable degrees of enrichment relative 
to Hprt gene control region in the adult heart (Figure 4C). In 
E10.5 mouse hearts, F1 and F2 were not found to be occupied, 
whereas F9 was occupied by endogenous TBX3 (Figure 4C).
Next, we determined the response of F1, F2, and F9 to T-box fac-
tors by means of luciferase assays. F1 and F2 were stimulated by 
TBX5 (activator) and repressed by both TBX3 and TBX2 (repres-
sors). F9 was not stimulated by TBX5, but responded to TBX2 
and TBX3 (Supplemental Figure 8B). The lack of response of F9 
to transcription factor stimulation prompted us to analyze this 
region further (Supplemental Figure 8, A and C). Deletion analy-
sis revealed a small, highly responsive fragment harboring bind-
ing sites for all transcription factors, indicative of the presence of 
sequences in F9 that act as suppressors.
To evaluate the in vivo activity pattern of the identified regulato-
ry fragments, we cloned the mouse fragments into an Hsp68/LacZ 
reporter vector. In this assay, F1 and F2 were grouped as a single 
fragment, because of their close spatial association and broad 
Figure 3
Scn5a and Scn10a are regulated by TBX3. (A) Overview of the ChIP-seq datasets within the Scn5a/Scn10a locus including flanking genes 
Scn11a and Exog. Top: TBX3, GATA4, NKX2-5, and p300 datasets (present study). Bottom: published ChIP-seq datasets showing tracks for 
biotinylated TBX5, GATA4, and NKX2-5 expressed in HL-1 cells (35); P300 in ED11.5 embryonic mouse heart (34); and P300 and POL2 in adult 
mouse heart (37). (B) In situ hybridization of Scn5a and Scn10a in E14.5 WT hearts showing expression pattern overlap, and the resemblance 
of the Scn5a downstream enhancer fragment F9 (F9 LacZ) with these expression patterns. Arrows denote areas of highest activity, in the atrial 
body and future ventricular conduction system components. san, sinoatrial node; ra, right atrium; la, left atrium; rv, right ventricle; lv, left ventricle; 
ivs, interventricular septum; drg, dorsal root ganglion. (C) In situ hybridization of Scn5a and Scn10a in the E17.5 sinoatrial node region showing 
complementary patterns to Tbx3 and partial overlap with Tbx5. Dotted outlines denote the sinus node region. Original magnification, ×5 (B); ×10 
(B, insets, and C).
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base coverage by p300 association sites (Figure 5A). The F1–F2 
construct showed cardiac activity in 7 of 9 embryos. The activity 
was weakest in the atria and in the ventricles and strongest in the 
region of the interventricular septum (Figure 4D). For F9, cardiac 
activity was observed in 6 of 6 embryos. Activity was present in 
the atria and ventricles, yet once again strongest in the interven-
tricular region (Figure 4E). The activity pattern of this regulatory 
fragment closely resembled that of both Scn5a and Scn10a, with 
highest activity in the atrial body and future ventricular conduc-
tion system components (Figure 3B). The TBX3-positive sinus 
node was devoid of lacZ expression, consistent with the notion 
that TBX3 represses this fragment. Recent evidence indicated 
that heart enhancers are not well conserved in evolution (34, 
58). Therefore, it is quite possible that the human orthologous 
Figure 4
In vitro and in vivo analyses of binding regions within the Scn5a/Scn10a locus. (A) Overview of 9 TBX3 ChIP-seq peaks within the Scn5a/Scn10a 
locus chosen for further investigation based on ChIP enrichment and overlap with GATA4 and NKX2-5 ChIP-seq peaks. Regions a and b repre-
sent 2 negative control regions used for ChIP-PCR (Supplemental Figure 7C). (B) Enhancer activity in vitro. Enhancers cloned upstream of pGL2 
and a minimal promoter were transfected into H10 cells with or without NKX2-5 and GATA4. Fragments F1, F2, and F6–F8 responded to addition 
of GATA4 and NKX2-5. F4 and F9 showed strong constitutive activity. *P < 0.05. (C) ChIP-qPCR assay for F1, F2, and F9, showing enrichment 
relative to Hprt for TBX3 in induced TBX3–expressing adult hearts and endogenous TBX3 in E10.5 hearts. ChIP-qPCR assays for endogenous 
TBX5, GATA4, and NKX2-5 were performed in WT adult mouse hearts. (D–G) Lateral views of whole embryos and magnified dorsal views of 
hearts (h) are shown for the reporter constructs with mouse and human F1–F2 and F9. Both human and mouse enhancers showed strong expres-
sion in the interventricular septum and, to a lesser extent, in the atria and ventricles. Ratios denote proportion of embryos showing cardiac activity.
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regions do not function as enhancers. To test this possibility, the 
human positional orthologs of the mouse fragments were used 
in the same in vivo transgenic reporter assay. Human F1–F2 and 
F9 both showed activity patterns highly similar to their mouse 
counterparts (Figure 4, F and G), which indicates that their func-
tion is evolutionarily conserved. Furthermore, we tested whether 
transcription factors bind to the human fragments. ChIP-qPCR 
on human ventricular samples revealed that NKX2-5 indeed occu-
pied these orthologous fragments in vivo (Figure 5C), thereby 
conserving their function (Figure 5B).
A genetic variant within the enhancer in SCN10A functionally affects a 
binding element for TBX3/TBX5. Recent GWAS studies have identi-
fied genetic loci influencing conduction system function, but the 
underlying mechanisms are not known (30–33, 54). The reported 
GWAS SNP rs6801957 is positioned in the conserved enhancer F1 
in SCN10A (Figure 5B) and may affect SCN5A/SCN10A expression. 
This SNP is positioned directly under a TBX3 ChIP-seq peak and 
is linked to a G-to-A substitution in the highly conserved portion 
of the T-box binding consensus sequence (Figure 5D). Enhancer 
fragments cloned from carriers of the major allele (i.e., G) could 
be stimulated by TBX5 and repressed by TBX3 in the presence of 
NKX2-5 and GATA4 (Figure 6A). In contrast, the fragment cloned 
from a minor allele (i.e., A) carrier did not respond to these T-box 
factors. Specific mutations generated in the fragments revealed 
that this SNP, but not other SNPs in this fragment that are in link-
age disequilibrium (LD), was involved in the T-box factor response 
(Figure 6A). Therefore, rs6801957 appeared to functionally affect 
gene expression of SCN10A/SCN5A. Furthermore, analysis of all 
other SNPs (n = 25) in LD (r2 > 0.6) revealed that rs6801957 was 
uniquely associated with peaks in our ChIP-seq datasets (Supple-
mental Table 11). Gel mobility shift assays using DNA probes mim-
icking both major and minor human alleles demonstrated a signifi-
cant reduction of T-box association with the minor allele compared 
with the major allele (Figure 6B and Supplemental Figure 9).
Next, we tested the activity of the 2.2-kb human F1–F2 enhancer 
fragment in zebrafish using the ZED vector, which allows simul-
taneous screening for transgenesis and enhancer-driven reporter 
activity in the heart (59); this analysis revealed that 70% of red 
fluorescent protein–expressing transgenic fish displayed enhanc-
er-driven green fluorescence in the heart (Figure 6C). When the 
minor allele for rs6801957 was introduced in the enhancer frag-
ment, this fraction dropped to about 40% (Figure 6D). When the 
minor allele for the SNP rs6795970 — which presumably affects 
SCN10A splicing and conduction (31) — was introduced, the frac-
tion of fish displaying enhancer-driven green fluorescence in the 
heart did not change. However, when rs6801957 was addition-
ally introduced, the fraction again dropped to about 40% (Figure 
6D). Taken together, these in vivo data confirmed that rs6801957 
affects enhancer function, which indicates that each allele carrying 
this SNP may express reduced levels of SCN10A, SCN5A, or both.
Figure 5
In vitro analysis of the homologous human genomic region F1–F2 and SNP associated with conduction. (A) Relative position of SNP rs6801957, 
located under overlapping peaks for ChIP-seq datasets TBX3, GATA4, NKX2-5, and p300. (B) Sequence conservation between species around 
rs6801957, located in a T-box binding motif. Gaps are denoted by asterisks. (C) ChIP-qPCR assay with NKX2-5 on human (h-) ventricular tissue 
for F1, F2, and F9 showed enrichment for all 3 fragments. (D) TBX3 binding motif found through TBX3 ChIP-seq.
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Discussion
Regulation of the cardiac electrical pattern by a network of transcriptional 
regulators and noncoding regulatory sequences of ion channel genes. GWAS 
identified common variants that modulated cardiac impulse con-
duction and repolarization. Several of these variants were posi-
tioned within noncoding DNA in the vicinity of genes encoding key 
cardiac transcription factors (e.g., TBX5 and TBX3) and ion channels 
(e.g., SCN5A and SCN10A), which suggested the presence of a regu-
latory network for the electrophysiological properties of the heart 
(29–33). Tissue-specific genes are regulated by enhancers, usually 
found in noncoding DNA, each driving a subset of its gene’s entire 
expression profile. These enhancers thus represent ideal candidates 
for involvement in complex diseases, such as arrhythmias, as vari-
ants in an individual enhancer result in cell type–specific changes 
in gene expression (60, 61). The genome-wide occupancy of several 
factors, including TBX5, NKX2-5, and GATA4, has previously been 
assessed in vitro in HL-1 cells (35), the factors being first biotinyl-
ated to enable their efficient immunoprecipitation. Furthermore, 
the occupancy of GFP-fused TBX20 was also recently assessed in 
the heart (48). Here, we derived a ChIP-seq protocol that allowed us 
to identify — to our knowledge for the first time — the occupancy of 
the native forms of cardiac transcription factors in the heart in vivo. 
Our data, together with the existing data, represent an invaluable 
resource providing a map for the location of tissue-specific enhanc-
ers in the adult heart that regulate genes involved in the local elec-
trophysiological properties of the heart.
Analysis of the genes interacting with and differentially regu-
lated by TBX3 indicated that TBX3 functions mainly as a tran-
scriptional repressor in vivo, consistent with previous observa-
tions using reporter assays (18, 62, 63). The gene set occupied by 
TBX3, repressed by TBX3, and reduced in the TBX3-positive AVC 
was highly enriched in genes encoding ion channels or involved in 
ion transport functions. This finding suggests that an important 
function of TBX3 in the conduction system is the direct regu-
lation of electrophysiological properties. Both Scn10a and Scn5a 
were among the channel genes suppressed by TBX3 (and stimu-
lated by TBX5), revealing functional parts of the regulatory net-
work indicated by the GWAS studies.
Figure 6
In vitro and in vivo analysis of genomic region F1–F2 and SNPs associated with conduction. (A) Luciferase assays performed in Cos7 showed 
that rs6801957 was involved in T-box factor response. Representative human major (G) alleles Maj1 and Maj2 responded to stimulation by 
TBX5 and repression by TBX3, whereas this effect on the minor (A) allele Min1 was significantly less. Mutating rs6801957 in these alleles 
showed a similar effect. *P < 0.01. Error bars represent SD. See Supplemental Table 10 for information on variants per allele. (B) EMSA showing 
relative oligonucleotide binding of MBP-TBX3 (+) compared with MBP only (–). MBP-TBX3 fusion associated well with both Nppa probe and 
human Maj1, but less with Min1 and Mut (containing a 3-bp mutation in the proposed T-box binding element). See Supplemental Figure 9 for 
quantification and statistical analysis. (C) Representative image of the zebrafish heart (dotted outline) containing ZED-Maj1, showing expres-
sion in the ventricle (V). A, atrium. Scale bar: 100 μm. (D) Percent GFP expression in hearts of zebrafish containing the major or minor allele 
for rs6801957. ZED represents the vector without genomic region F1–F2. Representative human major alleles Maj1 and Maj3 showed GFP 
expression in 60%–70% of the hearts of zebrafish containing these constructs. When major alleles were mutated into minor alleles (Maj1Mut 
and Maj3Mut), a significant reduction in GFP expression was found. The presence of rs6795970 in Maj3, also linked to conduction disease, 
had no significant effect on GFP expression in the heart.
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Identification of specific T-box factor target sites. TBX3-positive cardio-
myocytes of the adult conduction system were limited in number 
and not sufficient for the ChIP-seq assay. To overcome this problem, 
we used a model in which Tbx3 was ectopically activated in all car-
diomyocytes, assuming that this allows identification of binding 
sites occupied by TBX3 in the conduction system cardiomyocytes. 
Although the levels of Tbx3 expression in this model are moderate, 
and tolerated by the atria for a prolonged period (18), it is possible 
that TBX3 associates with sites normally occupied by other cardiac 
T-box proteins. Of the T-box proteins expressed in the adult myocar-
dium (i.e., TBX5 and TBX20), TBX5 most closely resembles TBX3 
(46, 47), and its binding sites are likely to be detected by ectopically 
expressed TBX3. Indeed, the consensus DNA binding site we identi-
fied for TBX3 binding resembles that identified for TBX5 (35), both 
of which diverge from previously defined T-box binding motifs (44, 
45). The recently described TBX20 motif derived from ChIP-seq data 
(48) differs from the TBX3/TBX5 motif and known consensus sites 
by 1 position with no nucleotide preference in the middle of the 
sequence. To rule out possible differences in the computational pre-
diction approach, we confirmed the TBX20 motif as published using 
MEME software. Thus, the observed difference in binding consensus 
may genuinely reflect a substantial in vivo functional difference in 
TBX20-specific gene target recognition. Assuming that the TBX20-
GFP fusion protein used in this study mimics native TBX20, this 
finding may reflect the closer phylogenetic relationship of TBX3 and 
TBX5, which belong to the TBX2 subfamily, than to TBX20, which 
belongs to the TBX1 subfamily (41, 64). Preferential binding of the 
different cardiac T-box factor subfamilies, each playing important 
roles in the heart, may greatly influence their target specificity, affect-
ing the mechanism underlying their function in heart development 
and gene regulation. In this respect, it will also be of great interest to 
fully unravel how T-box proteins interact with their target genes in 
the context of varying protein complexes to regulate gene expression.
Identification of functional enhancers for the cardiac sodium channels. 
SCN5A, encoding the cardiac sodium channel, is essential for heart 
function (26, 65). Modest reduction in SCN5A expression levels 
slows cardiac conduction and predisposes to arrhythmias under 
certain conditions (i.e., monogenic disease and drug therapy) (57, 
66). GWAS have implicated SCN10A in cardiac conduction. Its 
function in the heart remains unclear. Nav1.8 (encoded by Scn10a) 
may function in the myocardium to either decrease (31) or increase 
(33) conduction. Alternatively, Nav1.8 may function in the vagal 
innervation of the heart (67). We here identified key enhancers in 
Scn5a and Scn10a in mice and humans, providing more detailed 
insight into the link between the transcription factor network and 
the regulation of these important sodium channel genes in the 
heart. We hypothesized that these sequences represent key enhanc-
ers, both of which contribute to TBX5/TBX3-regulated expression 
patterns of Scn5a/Scn10a. More extensive analysis, such as chroma-
tin conformation capture (68) and genetic modification of mice, 
will be required to investigate the precise contributions of each of 
the enhancers to the regulation of the 2 sodium channel genes.
Recent ChIP-seq of p300 occupation in mouse and human 
hearts indicated that cardiac enhancers are not well conserved 
throughout evolution (34, 69). The sequences we identified by 
ChIP-seq in mice may not be functionally conserved in humans. 
Therefore, we performed ChIP for NKX2-5 on human ventricu-
lar samples and found that the orthologous human DNA frag-
ments were occupied by this factor. Furthermore, these elements 
were able to drive expression in patterns strikingly similar to 
their mouse counterparts. Together, these data revealed that the 
enhancers were functionally conserved in humans.
We provide the first functional evidence to our knowledge for the 
direct involvement of a human SNP in cardiac conduction system 
gene regulation. This SNP was found to be associated with increased 
PR/QRS duration, which suggests that the SNP — or a variant in 
LD with the SNP — decreases SCN5A/SCN10A expression. Our 
functional analysis indicated that the SNP itself converts a highly 
conserved nucleotide within the consensus T-box binding site and 
selectively affects TBX5/TBX3-mediated activity of the enhancer 
fragment, thereby reducing the cardiac activity of the enhancer. 
We hypothesize that the SNP affects the TBX5-activated/TBX3-
repressed expression of SCN5A/SCN10A in vivo. It is well possible 
that the enhancer regulates both SCN5A and SCN10A. Given that 
SCN5A provides a much larger contribution to sodium current 
and conductivity of the heart than does SCN10A, it seems probable 
that altered SCN5A expression underlies the observed influence of 
the SNP on conduction system function. Other genetic variants 
in noncoding DNA identified by GWAS in this and the other loci 
(30–33, 54) may influence conduction system function in a similar 
way. Nevertheless, the effect of the variant on conduction times was 
very small (33). Furthermore, the GWAS identified heterozygous 
variants associated with conduction system function, whereas in 
our functional studies, we studied the effect of the isolated variants, 
equivalent to homozygosity for the variant. In this respect, it is likely 
that multiple genetic variants together can cause a cumulative bio-
logically significant modulation of sodium channel gene expression.
In summary, the present study identified a set of enhancers and 
key binding factors important for cardiac conduction system devel-
opment and function, and further identified disrupted transcrip-
tion factor binding as a mechanism likely underlying the effect of a 
genetic variant at the SCN10A/SCN5A locus on cardiac conduction. 
Uncovering the molecular network and the noncoding regions reg-
ulating conduction system function will help to understand how 
they affect conduction system function, and may offer tools to pre-
dict disease susceptibility and progression among individuals (70).
Methods
ChIP sequencing from adult mouse heart. CAG-CAT-TBX3–heterozygous 
(CTBX3+/–) mice (18) were crossed with Myh6MCM mice (39). Tamoxifen 
(catalog no. T5648; Sigma-Aldrich) was injected intraperitoneally (100 mg 
per mouse per day) at 4-day intervals in adult males. Hearts were removed 
on day 5, prior to the onset of heart dysfunction (40). Quantitative RT-PCR 
was performed to determine the efficiency of recombination. For NKX2-5, 
GATA4, and p300 ChIPs, hearts were isolated from adult FVB males. Tissues 
were cross-linked in 1% (p300) or 2% (TBX3, GATA4, and NKX2-5) formal-
dehyde for 30 minutes at room temperature. Cross-linking was quenched 
by addition of 0.125M glycine. Tissues were dissociated by IKA Ultra Tur-
rax T5 FU, pelleted, and resuspended in cold lysis buffer (50 mM Tris-HCl, 
pH 8.1; 10 mM EDTA, pH 8.0; 1% SDS; and 1× Protease Inhibitor Cocktail 
[Roche]). Nuclei were obtained by use of a tight glass dounce homogenizer. 
Cross-linked nuclei were sonicated under conditions established to yield 
an average fragment size of approximately 300 bp. Antibodies TBX3 (A-20, 
sc-17871, lot no. J0306), TBX5 (C-20, sc-17866, lot no. D1708), NKX2-5 
(N-19, sc-8697, lot nos. A1109 and J2010), GATA4 (C-20, sc-1237, lot no. 
F3010), and p300 (N-15, sc-583, lot no. K3009) were purchased from Santa 
Cruz. Immunoprecipitation, washing, elution, and reverse cross-linking were 
performed as previously described (71). Quality of the ChIP was assessed 
with primers on locations of known cardiac enhancers. Quality was also 
previously qualitatively assessed by noting peaks at published T-box respon-
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cleus of 0.5-day-old fertilized FVB/N eggs, which were subsequently trans-
ferred into the oviducts of CD-1 pseudopregnant foster females (Cyagen 
Inc.). At least 200 injections were performed per construct. Embryos were 
harvested and stained with X-gal to detect LacZ activity, and yolk sacs were 
processed for PCR genotyping.
In vivo zebrafish enhancer assay. Enhancer sequences Maj1, Maj1Mut, 
Maj3, and Maj3Mut were amplified by PhusionTAQ PCR (New England 
Biolabs) and cloned into the ZED vector (59) by Gateway technology 
(Life Technologies BV). ZED-Maj1, ZED-Maj1Mut, ZED-Maj3, and ZED-
Maj3Mut were injected in WT zebrafish embryos at the 1-cell stage at a 
final concentration of 15 ng/μl in the presence of 25 ng/μl TOL2 trans-
posase RNA. Embryos were kept at 28.5°C in E3 medium and scored for 
heart-specific red fluorescent protein, and subsequently heart-specific 
GFP, fluorescence at 48 hours post fertilization (hpf) on a Leica MZFLIII 
fluorescence stereomicrocope (Leica Microsystems GmbH) set up with 
appropriate fluorescence filters.
In vivo imaging of the embryos at 48 hpf was carried out on a Zeiss 
Axioskop 2 Mot plus fluorescence microscope (Carl Zeiss MicroImaging 
GmbH) mounted with a Leica DFC490 CCD camera (Leica Microsystems) 
using appropriate fluorescence filters.
Other methods. Procedures for quantitative expression analysis, luciferase 
assays, in situ hybridization, and EMSA were performed as described previ-
ously (18). See Supplemental Methods and Supplemental Tables 5, 7, and 
8 for details.
Statistics. Unless otherwise indicated, a P value less than 0.05 was consid-
ered significant. See Supplemental Methods for details.
Study approval. This investigation conformed to NIH guidelines (Guide for 
the Care and Use of Laboratory Animals. NIH publication no. 85-23. Revised 
1996). All animal work was approved by the Animal Experimental Com-
mittee of the Academic Medical Center, University of Amsterdam, and 
carried out in compliance with Dutch government guidelines. Investiga-
tions using the human ventricular sample conformed to the principles 
outlined in the Helsinki Declaration of the World Medical Association. 
Use of human cardiac material was approved by the Ethical Review Board 
of the Medical Center of the University of Szeged.
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sive enhancers (52). Material was used for library preparation with standard 
NEBNext library kit protocol for Illumina sequencing (lot nos. E6000S/L 
and E6040S/L; New England BioLabs). ChIP-seq data were deposited in 
NCBI’s Gene Expression Omnibus (72) under accession no. GSE35151 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35151).
ChIP-qPCR was performed on a Roche LightCycler 480 System using 
Sybr Green detection. Fold enrichment indicates the ratio of ChIPed DNA 
to a negative control region in the Hprt locus, normalized for input DNA. 
Tested locations were randomly chosen using the Galaxy software inter-
face. Primer sequences are provided in Supplemental Table 6.
ChIP-qPCR on human ventricular samples. The human ventricular sample 
used for ChIP was from a nondiseased human heart that was technically 
unusable for transplantation based on logistic considerations and was pro-
vided by A. Varró (University of Szeged, Szeged, Hungary). Before cardiac 
explantation, the organ donor did not receive medication except dobuta-
mine, furosemide, and plasma expanders.
Processing of ChIP sequencing data. Sequencing results were run through 
the standard Illumina GAPipeline (version 1.3 for GAII runs) to convert 
images to reads of 36 bp in length (unaligned sequences produced by the 
Illumina Genome Analyzer) and edit for quality (FIRECREST, Bustard, and 
GERALD). Reads were then processed and aligned to the mouse reference 
genome (Mm9; NCBI Build 37) as previously described, allowing a maximum 
of 2 mismatches and retaining only sequences with unique alignments (73).
Peaks were extracted and defined from the wiggle files containing the cov-
erage per bp using an in-house algorithm that returns peak start and stop 
coordinates in a BED file format. BED files for TBX3, GATA4, and NKX2-5 
are shown in Supplemental Table 12. Locations of known cardiac enhancers 
were checked for transcription factor binding as a quality control for these 
datasets. See Supplemental Methods for the exact settings for peak calling.
Gene sets were extracted from UCSC refGene for the mouse using the Gal-
axy software interface. We allocated promoter regions for the 27,585 mouse 
genes currently listed under RefGene; a promoter was defined as the 1-kb 
upstream region of an annotated transcriptional start site. Overlaps between 
gene regions and peak regions were identified using Galaxy. For determining 
the intersection between gene arrays and TBX3 ChIP-seq peak regions, sig-
nificantly up- or downregulated genes from the various microarray datasets 
were assigned coordinates using the Biomart Central Portal. All chromosom-
al coordinates were subsequently extended both up- and downstream by 1 
kb. Coordinates were then intersected using the Galaxy software interface. 2 
control gene sets were generated, both for the induced TBX3 array analysis 
and the AVC/working myocardium array analysis, using 6 sets of equiva-
lent numbers of unique genes, randomly extracted from the nonsignificant 
genes of the latter study and further treated in exactly the same way as the 
test gene sets. Statistical analysis of the significance of enrichment between 
intersects and controls was carried out using a Z test, which uses the normal 
approximation of the binomial distribution to compare proportions (74, 
75). Microarray data were deposited in NCBI’s Gene Expression Omnibus 
(72) with accession nos. GSE13614 and GSE31969.
Proteins assigned to overlaps were extracted using Galaxy and further ana-
lyzed using the DAVID bioinformatics resource gene ontology (GO) analysis 
software (49, 50). Unique gene names were called using chromosome loca-
tions via the BioMart Central Portal. Motif analysis was performed with 
MEME (42) using 600 random peaks, with an average length of approxi-
mately 165 bp, per total dataset. For scanning ChIP-seq peaks with known 
transcription factor motifs, position weight matrices were obtained from 
JASPAR (43, 44) and TRANSFAC (version 11.3; ref. 45) databases.
Transgenic mouse enhancer assay. Enhancer candidate regions of 2–3 kb in 
the Scn5a/Scn10a locus were cloned into the Hsp68-LacZ reporter vector as 
previously described (76). Genomic coordinates of the amplified regions 
are provided in Supplemental Table 9. DNA was injected into the pronu-
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